Regeneron COVID-19 treatment enters final stage trials | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
June 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JUNE 10, 2025
Regeneron COVID-19 treatment enters final stage trials

Coronavirus chronicle

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm

Related News

  • Yes, everyone really is sick a lot more often after covid
  • Pentagon's secret anti-vax campaign against China during the pandemic
  • Bangladesh reports one Covid-19 death, 37 positive cases
  • 3rd, 4th doses of Covid-19 vaccination underway
  • WHO warns Covid still a threat

Regeneron COVID-19 treatment enters final stage trials

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm
Regeneron COVID-19 treatment enters final stage trials

The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19.

The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus' "spike protein" which it uses to invade human cells.

The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus — for example through a person in their household.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US.

"We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an antiviral antibody cocktail that could be available much sooner than a vaccine," said Regeneron President George Yancopoulos.

At the same time, Regeneron announced it was moving to the final stages of a trial to determine the drug cocktail's ability to treat both hospitalized and non-hospitalized COVID-19 patients.

This will involve around 1,850 hospitalized and 1,050 non-hospitalized patients in the US, Brazil, Mexico and Chile, with preliminary data expected later this summer.

Regeneron scientists evaluated thousands of antibodies harvested from genetically modified mice and from humans, identifying the two they found to be most potent against the SARS-CoV-2 virus, while not competing against each other.

The company uses a multi-antibody strategy to decrease the chances that the virus will mutate in order to evade the blocking action of a single antibody, an approach it detailed in a recent study in Science.

Last year, a triple antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.

Top News

Regeneron / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Chief Adviser Muhammad Yunus leaves for a four-day visit to the United Kingdom from the Dhaka airport on 9 June 2025. Photo: CA Press Wing
    CA Yunus leaves for UK; discussion expected on renewable energy investment, laundered money
  • California Governor Gavin Newsom. File Photo: REUTERS/Fred Greaves
    California Governor Newsom to sue Trump over National Guard deployment amid LA protests
  • File photo of Shafiqul Alam. Photo: Collected
    Positive message for country if CA meets Tarique, but no decision on meeting yet: Shafiqul tells Somoy

MOST VIEWED

  • On left, Abdullah Hil Rakib, former senior vice president (SVP) of BGMEA and additional managing director of Team Group; on right, Captain Md Saifuzzaman (Guddu), a Boeing 787 Dreamliner pilot for Biman Bangladesh Airlines. Photos: Collected
    Ex-BGMEA SVP Abdullah Hil Rakib, Biman 787 pilot Saifuzzaman drown in boating accident in Canada
  • A photo showing the former president on his return to Dhaka today (9 June). 
Source: Collected
    Former president Abdul Hamid returns to Bangladesh from Thailand
  • File Photo: British MP Tulip Siddiq attends a news conference with Richard Ratcliffe, the husband of jailed British-Iranian aid worker Nazanin Zaghari-Ratcliffe, in London, Britain October 11, 2019. Photo: REUTERS/Peter Nicholls/File Photo
    Tulip requests CA Yunus for a meeting over corruption allegations: Guardian
  • Representational image. Photo: Reuters
    Bangladesh reports 3 more Covid-19 cases
  • Muhammad Yunus (L) and Narendra Modi. Photo: Collected
    Modi sends Eid-ul-Adha greetings, Yunus calls for continued bilateral cooperation
  • Photo: Reuters
    Trump says Musk relationship over, warns of 'serious consequences' if he funds Democrats

Related News

  • Yes, everyone really is sick a lot more often after covid
  • Pentagon's secret anti-vax campaign against China during the pandemic
  • Bangladesh reports one Covid-19 death, 37 positive cases
  • 3rd, 4th doses of Covid-19 vaccination underway
  • WHO warns Covid still a threat

Features

File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

13h | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

2d | Bangladesh
Illustration: TBS

Unbearable weight of the white coat: The mental health crisis in our medical colleges

5d | Panorama
(From left) Sadia Haque, Sylvana Quader Sinha and Tasfia Tasbin. Sketch: TBS

Meet the women driving Bangladesh’s startup revolution

5d | Panorama

More Videos from TBS

US and China to meet in London for trade talks

US and China to meet in London for trade talks

2h | TBS World
The forbidden point on Cox's Bazar beach is like a death trap

The forbidden point on Cox's Bazar beach is like a death trap

4h | TBS Today
Israeli forces seize Gaza aid boat carrying Greta Thunberg

Israeli forces seize Gaza aid boat carrying Greta Thunberg

6h | TBS World
Which way will the anti-immigration campaign in Los Angeles turn?

Which way will the anti-immigration campaign in Los Angeles turn?

6h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net